Susan E. Pratt

1.4k total citations
26 papers, 986 citations indexed

About

Susan E. Pratt is a scholar working on Molecular Biology, Oncology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Susan E. Pratt has authored 26 papers receiving a total of 986 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Oncology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Susan E. Pratt's work include Drug Transport and Resistance Mechanisms (7 papers), Pharmacological Effects and Toxicity Studies (6 papers) and Histone Deacetylase Inhibitors Research (4 papers). Susan E. Pratt is often cited by papers focused on Drug Transport and Resistance Mechanisms (7 papers), Pharmacological Effects and Toxicity Studies (6 papers) and Histone Deacetylase Inhibitors Research (4 papers). Susan E. Pratt collaborates with scholars based in United States, Canada and United Kingdom. Susan E. Pratt's co-authors include Anne H. Dantzig, Michaël Pollak, Robert L. Shepard, William L. Perry, Paul A. Johnston, Ramani A. Kandasamy, James J. Starling, George E. Sandusky, Karen Mintze and Linda B. Tabas and has published in prestigious journals such as Analytical Chemistry, Cancer Research and Clinical Cancer Research.

In The Last Decade

Susan E. Pratt

26 papers receiving 965 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan E. Pratt United States	15	553	425	155	131	114	26	986
Chee M. Ng United States	23	481 0.9×	503 1.2×	291 1.9×	97 0.7×	84 0.7×	57	1.7k
Julie Bullock United States	17	515 0.9×	467 1.1×	126 0.8×	123 0.9×	69 0.6×	26	1.6k
Barry Hoffman Canada	18	545 1.0×	519 1.2×	257 1.7×	252 1.9×	244 2.1×	30	1.5k
Ai Tamura Japan	18	677 1.2×	402 0.9×	221 1.4×	48 0.4×	66 0.6×	30	1.0k
Milin Acharya United States	19	637 1.2×	934 2.2×	162 1.0×	107 0.8×	149 1.3×	36	1.9k
Yvonne Lau United States	14	638 1.2×	493 1.2×	221 1.4×	125 1.0×	66 0.6×	30	1.3k
Dietmar Schwab Switzerland	14	305 0.6×	415 1.0×	79 0.5×	154 1.2×	56 0.5×	26	1.1k
Nicola F. Smith United States	16	605 1.1×	618 1.5×	222 1.4×	36 0.3×	56 0.5×	22	1.3k
Chris Liddle Australia	14	338 0.6×	371 0.9×	122 0.8×	169 1.3×	37 0.3×	16	1.2k
Robert A.B. van Waterschoot Netherlands	16	725 1.3×	332 0.8×	233 1.5×	62 0.5×	49 0.4×	20	1.2k

Countries citing papers authored by Susan E. Pratt

Since Specialization

Citations

This map shows the geographic impact of Susan E. Pratt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan E. Pratt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan E. Pratt more than expected).

Fields of papers citing papers by Susan E. Pratt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan E. Pratt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan E. Pratt. The network helps show where Susan E. Pratt may publish in the future.

Co-authorship network of co-authors of Susan E. Pratt

This figure shows the co-authorship network connecting the top 25 collaborators of Susan E. Pratt. A scholar is included among the top collaborators of Susan E. Pratt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan E. Pratt. Susan E. Pratt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pratt, Susan E., et al.. (2023). Uncovering diffusive states of the yeast membrane protein, Pma1, and how labeling method can change diffusive behavior. The European Physical Journal E. 46(6). 42–42. 2 indexed citations

Wu, Wenjuan, Constance King, Gregory P. Donoho, et al.. (2018). Abstract 336: Anti-tumor activity of the Chk1 inhibitor prexasertib (LY2606368) as a single agent in triple negative breast cancer models. Cancer Research. 78(13_Supplement). 336–336. 4 indexed citations

Wu, Wenjuan, Shripad V. Bhagwat, Constance King, et al.. (2017). Abstract 317: Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4 and CDK6 inhibitor (abemaciclib) enhances antitumor efficacy in KRAS mutant non-small cell lung cancer (NSCLC). Cancer Research. 77(13_Supplement). 317–317. 1 indexed citations

Pratt, Susan E., Robert L. Shepard, Gregory P. Donoho, et al.. (2013). Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts. Molecular Cancer Therapeutics. 12(4). 481–490. 24 indexed citations

Pratt, Susan E., et al.. (2013). Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells. Clinical Cancer Research. 19(5). 1159–1168. 90 indexed citations

Pratt, Susan E., Raymond Gilmour, Nigel Brooks, Edward K. L. Chan, & Louis F. Stancato. (2012). 404 LY2228820 Dimesylate, a P38 MAPK Inhibitor, Demonstrates Anti-Neoplastic Activity in Mouse Models of Human Ovarian Cancer. European Journal of Cancer. 48. 123–123. 2 indexed citations

Pratt, Susan E., et al.. (2011). Abstract 2981: Carboxylesterase 2 hydrolyzes a gemcitabine prodrug (LY2334737) and provides a patient tailoring biomarker. Cancer Research. 71(8_Supplement). 2981–2981. 2 indexed citations

Holzer, Timothy R., Kathleen M. Heinz-Taheny, Darryl Ballard, et al.. (2010). Abstract B31: Potential for patient tailoring for prodrug of gemcitabine (LY2334737) by assessment carboxylesterase II expression in solid tumor biopsies. Clinical Cancer Research. 16(14_Supplement). B31–B31. 2 indexed citations

Pratt, Susan E., et al.. (2010). Abstract B36: Identification of carboxylesterase 2 as a hydrolase that cleaves the prodrug of gemcitabine LY2334737. Clinical Cancer Research. 16(14_Supplement). B36–B36. 1 indexed citations

10.

Wickremsinhe, Enaksha, Barry S. Lutzke, Barry Jones, et al.. (2010). Quantification of Gemcitabine Incorporation into Human DNA by LC/MS/MS as a Surrogate Measure for Target Engagement. Analytical Chemistry. 82(15). 6576–6583. 17 indexed citations

11.

Roumie, Christianne L., Tom A. Elasy, Kenneth A. Wallston, et al.. (2007). Clinical Inertia: A Common Barrier to Changing Provider Prescribing Behavior. The Joint Commission Journal on Quality and Patient Safety. 33(5). 277–285. 54 indexed citations

12.

Pratt, Susan E., Robert L. Shepard, Ramani A. Kandasamy, et al.. (2005). The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Molecular Cancer Therapeutics. 4(5). 855–863. 186 indexed citations

13.

Pratt, Susan E., et al.. (2005). Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. European Journal of Pharmaceutical Sciences. 27(5). 524–532. 36 indexed citations

14.

Dantzig, Anne H., Robert L. Shepard, Susan E. Pratt, et al.. (2003). Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP-binding cassette (ABC) drug transporters. Biochemical Pharmacology. 67(6). 1111–1121. 31 indexed citations

15.

Laska, Dennis A., Susan E. Pratt, Ramon F. Hanssen, et al.. (2002). CHARACTERIZATION AND APPLICATION OF A VINBLASTINE-SELECTED CACO-2 CELL LINE FOR EVALUATION OF P-GLYCOPROTEIN. In Vitro Cellular & Developmental Biology - Animal. 38(7). 401–401. 17 indexed citations

16.

Ma, Liandong, Susan E. Pratt, Jin Cao, et al.. (2002). Identification and characterization of the canine multidrug resistance-associated protein.. PubMed. 1(14). 1335–42. 20 indexed citations

17.

Sandusky, George E., Karen Mintze, Susan E. Pratt, & Anne H. Dantzig. (2002). Expression of multidrug resistance‐associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology. 41(1). 65–74. 88 indexed citations

18.

Pratt, Susan E., et al.. (1994). Evidence that modulation of glucose transporter intrinsic activity is the mechanism involved in the allose‐mediated depression of hexose transport in mammalian cells. Journal of Cellular Physiology. 161(3). 580–588. 10 indexed citations

19.

Pratt, Susan E. & Ralph J. Germinario. (1994). Differential Glycosylation of the Glucose Transporter Coincides with Enhanced Sugar Transport in Respiration Deficient Cells. Biochemical and Biophysical Research Communications. 200(3). 1313–1320. 8 indexed citations

20.

Pratt, Susan E. & Michaël Pollak. (1994). Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) Inhibits Estrogen-Stimulated Breast Cancer Cell Proliferation. Biochemical and Biophysical Research Communications. 198(1). 292–297. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact